FINWIRES · TerminalLIVE
FINWIRES

Abbott Cuts 2026 Earnings Outlook Following First-Quarter Beat

-- Abbott Laboratories (ABT) lowered its full-year earnings outlook on Thursday to reflect the acquisition of cancer diagnostics company Exact Sciences, while the healthcare firm reported first-quarter results above market estimates.

The company now anticipates adjusted earnings of $5.38 to $5.58 per share for 2026, including a $0.20 dilution related to the Exact Sciences purchase. The company previously expected adjusted EPS to come in between $5.55 and $5.80 for the year, while the current consensus on FactSet is for $5.60.

Abbott acquired Exact Sciences in March.

"The acquisition of Exact Sciences adds another high-growth business to the Abbott portfolio, further strengthening our confidence in delivering accelerating growth as we move through the year," Abbott Chief Executive Robert Ford said in a statement.

Comparable sales, which includes the prior and current year sales of Exact Sciences, are pegged to grow by 6.5% to 7.5% for 2026, according to the company.

Abbott's shares fell 4.1% in Thursday trade, taking its year-to-date loss to 22%.

For the three-month period ended March, the firm's adjusted EPS rose to $1.15 from $1.09 the year before, surpassing the Street's view for $1.14. Sales improved 7.8% to $11.16 billion, topping the average analyst estimate of nearly $11 billion. Comparable sales were up 3.7%.

Diagnostics sales rose 6.1% year over year to $2.18 billion, while the nutrition segment dropped 6% to $2.02 billion amid lower sales volume and pricing actions in the previous quarter, according to the company. Revenue in the established pharmaceuticals division climbed 13% to $1.43 billion.

Sales in the global medical devices business jumped 13% to $5.54 billion, led by gains of 17% each in rhythm management and electrophysiology, Abbott said. Within the segment, the company recorded double-digit growth in heart failure and diabetes care.

For the second quarter, Abbott forecasts adjusted EPS of $1.25 to $1.31, while the Street is looking for $1.36.

Price: $97.09, Change: $-4.43, Percent Change: -4.36%

相關文章

Australia

IBM第一季調整後獲利及營收均成長;盤後股價下跌

IBM(IBM)週三晚間公佈了第一季調整後每股收益為1.91美元,高於去年同期的1.60美元。 FactSet調查的分析師先前預期為1.81美元。 截至3月31日的第一季,IBM營收從去年同期的145億美元增至159億美元。 FactSet調查的分析師先前預期為156億美元。 IBM股價在盤後交易下跌6.8%。

$IBM
Mining & Metals

塔拉尼斯資源公司報告銀杯礦區早期勘探取得積極成果

塔拉尼斯資源公司(Taranis Resources,股票代號:TRO.V)週三表示,該公司位於不列顛哥倫比亞省東南部歷史悠久的銀杯礦區(Silver Cup Mining District)的索爾(Thor)項目擴容工作已初見成效。 該公司結合歷史土壤樣本、鑽探數據、地球物理勘測和過往採礦記錄,以更好地了解其認為可能具有區域規模的礦藏,並將其在該地區的礦權面積擴大至6000多公頃。 該公司表示:“結合塔拉尼斯先前對索爾礦區進行的廣泛勘探,這項長期被遺忘的勘探工作揭示了一個更大的礦化系統,將索爾礦床置於一個更廣闊、前景廣闊的地質框架中。” 該公司還表示,這項擴容工作與對索爾礦床新區域的鑽探工作同步進行,包括諾特蘭(Nortran)、博爾(Borr)和一點鐘(One O'clock)靶區。在塔拉尼斯新獲得的東部礦權區內,有數十條與索爾礦區類似的高品位近地表金屬礦脈。該公司補充說,這些礦藏尚未按照NI 43-101資源估算標準進行鑽探,這為公司提供了一個絕佳的機會,可以更深入地了解這個歷史悠久的金銀礦區。 Taranis股票在多倫多證券交易所創業板收盤上漲0.005美元,至0.185美元。

$TRO.V
Australia

特斯拉(TSLA)第一季財報快訊:營收223.9億美元,高於FactSet預期的221億美元。

Price: $387.50, Change: $+1.07, Percent Change: +0.28%

$TSLA